Dr. Risch does a great job explaining why the trials showing HCQ/zinc/azithromycin to be ineffective are flawed, and why it does actually work. I'm gonna trust the guy that has actually researched this far more than anyone at the CDC or FDA - and especially the Great Fauchino.
• Every one of the now 8 studies of high-risk outpatient hydroxychloroquine (HCQ) use has shown significant 2-fold or better risk reduction for hospitalization or mortality.
• The numerous systematic case-series studies have shown exceedingly good treatment benefit vs mortality. They have already saved thousands of lives.
• The “natural experiment” studies of population medication responses provide compelling evidence of temporal relations between medication use and mortality reduction.
• The RCT studies proclaimed supposedly as definitively showing no benefit of HCQ use in outpatients have all involved almost entirely low-risk subjects with virtually no hospitalization or mortality events and are uninformative and irrelevant for bearing upon these risks according to HCQ use in high-risk outpatients.
• Dr. Lawrence Kacmar, in Aurora IL, has treated 68 high-risk outpatients with HCQ+azithromycin and observed zero deaths (Risch, 2020a). Dr. Brian Procter, in McKinney, TX, has treated 50 high-risk outpatients with HCQ+ azithromycin+zinc sulfate+losartan+aspirin and observed zero deaths in his first series, and another 143 with one death in his second series (Risch, 2020a; Procter B, McKinney Family Medicine, McKinney TX, personal communication, 2020). Dr. Steven Crawford, in a Festus, MO nursing home, has treated 52 high-risk outpatients with HCQ+rehydration and observed zero deaths (Risch, 2020a). Dr. Brian Tyson, in El Centro CA, has treated 450 high-risk outpatients with HCQ+azithromycin and observed zero deaths (Risch, 2020a; Tyson B, personal communication, 2020). In total, these physicians have reported in the literature or to me, treatment of 1,568
high-risk outpatients with HCQ+azithromycin etc. and observed among them 3 COVID-19-related deaths, for mortality of 0.19%. This low mortality can only be described as stupendous and a tribute to the clinical engagement of these physicians, and completely distinguishable from the CT 12.8% mortality or similar risks of untreated high-risk outpatients in other US states.
• It is readily apparent that every one of the studies of high-risk outpatient HCQ use have shown 2-fold or better risk reduction for hospitalization or mortality, and that the numerous systematic case-series studies have shown exceedingly good treatment benefit vs mortality. The “natural experiment” studies of population responses provide compelling evidence of temporal relations between medication use and mortality. The RCT studies proclaimed as definitively showing no benefit of HCQ use in outpatients have all involved almost entirely lowrisk subjects with virtually no information about risks of hospitalization and mortality and are irrelevant for bearing upon HCQ use in high-risk patients.